Global Artificial Organ Market (By Type) – Prospective Landscape, Size, Share, Growth, Opportunities and Industry Forecast 2018 – 2025

Published DateReport CodeNo. of PagesReport Format
Sept – 2019AMR-9002110PDF / Excel

SelectLicense Type

North America dominated the artificial organs market in 2018 and is expected to do so over the forecast period.

An artificial organ is a medical device embedded or implanted into the human body to simulate or improve the organ’s biological function. Increasing the incidence of cardiovascular diseases (CVDs) such as heart disease, strokes, chronic kidney disease, diabetes, increasing aging populations and hearing disorders are likely to boost artificial organ demand. The spike in unhealthy diets and physical inactivity, in turn, might have led to an increase in cardiovascular disorders and chronic conditions, and resulting in higher demand for devices such as total artificial hearts and pacemakers.

One of the major trends gaining popularity in the global artificial organs industry is the advent of total artificial hearts (TAH). TAH has started to emerge as a successful treatment option for end-stage biventricular heart failure patients. Its use in a heart-to-heart transplant technique has previously been approved globally. As a matter of fact, this artificial organ market analysis underlines that, over the forecast period, such factors will keep driving the global artificial organ market at a fastest CAGR of nearly 11%.

Organ necessity exceeds the supply of donated organs. Even today, there are lots of elderly patients for organ transplants, but not everybody can get it done due to the current limited supply of organ transplantation. According to the American Transplant Foundation, in the United States, around 122,000 patients are waiting for organ transplants and nearly 20 people are dying every day due to organ transplants shortages. Not only is organ shortage a problem, it is also a major issue to find a correct organ for the body. Biomedicine is a growing shift in the world of science to solve this issue. Biomedicine is a medical research division that seeks genetic and other biological-science values for the growth of artificial organs in medical practice. It is possible to deliver the right organ to the patient at the right time due to biomedicine. Biomedicine is therefore a spark of hope for those who experience organ failure.

The growing number of renal failure and dialysis due to faulty way of living, excessive number of accidents, rapid ageing population, illnesses and increased number of individuals waiting for organ transplants are the main factors that drive the market. Researchers are carrying out studies on renewable energy cells that could use human body glucose and oxygen to produce electricity. Such factors give the artificial organ industry a potential to grow further at a significant rate.

Several companies work on developing artificial organs with improved comfort for patients. Companies are also making significant R&D investments to satisfy end-user requirements, which are expected to boost demand for artificial organs further. The key global players of Artificial Organ market are Edwards Lifesciences Corp., HeartWare International, Inc., Abiomed, Inc. Cochlear Limited, Boston Scientific Corporation, B. Braun Melsungen AG, Getinge AB, Baxter International Inc., Medtronic PLC, and Fresenius Medical Care.

Artificial organs are engineered equipment that are inserted in a human body to fill or operate a particular function of a biological organ. They are composed of the plastic seeded from the transplant recipient with stem cells, therefore the immune system of the body does not refuse to accept the unnatural organ. These machines do not have to be continually tied to a power source or any other static resource and can keep patients with severe organ failure safe and working for a long time.

The key factors driving the artificial organ market are the ageing global population and a subsequent rise in the number of people who suffer from organ failures. The demand for artificial organs has resulted due to the increasing road accidents and injuries leading to surgical procedures coupled with increasing public awareness of advances in medical technology. On the other hand, it is expected that high transplantation costs and minimal surgical expertise will limit market growth in most regions. However, when required, the absence and shortage of organ donors has encouraged the development of new technologies for artificial organs worldwide.

Artificial kidney segment is believed to have the biggest size in the market and is expected witness strong growth throughout the forecast period. The End-Stage Renal Disease (ESRD) tends to affect more than 600,000 patients per year in the United States and an approximately 1.8 million patients globally. Those living with ESRD make up only less than 1% of the Healthcare-covered population, but make up 5% to 7% of the Healthcare budget. Every year, the percentage of patients diagnosed with ESRD in the United States is growing by 4% to 5%.

Depending on the treatment with ESRD, mortality rates vary. Those on medication have a mortality rate of 25-30 percent after one year of diagnosis, with a life expectancy of 30-35 percent for five years. As survival rates increase due to medication, there is increased demand for unnatural kidneys, which drives this segment’s growth.

North America presently dominates the artificial organs market, and its stronghold is expected to continue for a few years to come. Due to excessive increased demand for artificial organs, this region is projected to increase its share of the market in the future. Each year, the U.S. spends a significant portion of its gross domestic product on medical care. According to the Organization for Economic Co-operation and Development (OECD)’s latest 2018 report, about 18% of Gross domestic product is spent on healthcare. A substantial portion of this goes into transplants in the United States. The United States thus continues to hold the largest proportion in the North American artificial organ market.

The market for artificial organs is competitive and consists of several major players. With reference to market share, the industry is currently controlled by few of the major players. Nevertheless, mid-size to smaller businesses are expanding their market presence with product innovations and technological advancements by bringing in new technologies with lower costs.

The key global players of Artificial Organ market are Edwards Lifesciences Corp., HeartWare International, Inc., Abiomed, Inc. Cochlear Limited, Boston Scientific Corporation, B. Braun Melsungen AG, Getinge AB, Baxter International Inc., Medtronic PLC, and Fresenius Medical Care.

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025 – Key Industry Dynamics

  • 3.1. Key Market Drivers
  • 3.2. Key Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Future Trends
  • 3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

Chapter 5. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025 – By Type

  • 5.1. Artificial Kidney
  • 5.2. Artificial Heart
  • 5.3. Cochlear Implants
  • 5.4. Artificial Pancreas
  • 5.5. Others

Chapter 6. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025 – By Region

  • 6.1. North America
  • 6.2. Europe
  • 6.3. Asia-Pacific
  • 6.4. Latin America
  • 6.5. Middle East & Africa

Chapter 7. North America Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 7.1. North America Artificial Organ Market – By Type
    • 7.1.1.Artificial Kidney
    • 7.1.2.Artificial Heart
    • 7.1.3.Cochlear Implants
    • 7.1.4.Artificial Pancreas
    • 7.1.5.Others
  • 7.2. North America Artificial Organ Market – By Country
    • 7.2.1.U.S.
    • 7.2.2.Canada

Chapter 8. Europe Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 8.1. Europe Artificial Organ Market – By Type
    • 8.1.1.Artificial Kidney
    • 8.1.2.Artificial Heart
    • 8.1.3.Cochlear Implants
    • 8.1.4.Artificial Pancreas
    • 8.1.5.Others
  • 8.2. Europe Artificial Organ Market – By Country
    • 8.2.1.Germany
    • 8.2.2.France
    • 8.2.3.UK
    • 8.2.4.Spain
    • 8.2.5.Italy
    • 8.2.6.Rest of Europe

Chapter 9. Asia-Pacific Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 9.1. Asia Pacific Artificial Organ Market – By Type
    • 9.1.1.Artificial Kidney
    • 9.1.2.Artificial Heart
    • 9.1.3.Cochlear Implants
    • 9.1.4.Artificial Pancreas
    • 9.1.5.Others
  • 9.2. Asia-Pacific Artificial Organ Market – By Country
    • 9.2.1.China
    • 9.2.2.India
    • 9.2.3.Japan
    • 9.2.4.South Korea
    • 9.2.5.Rest of Asia-Pacific

Chapter 10. Latin America Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 10.1. Latin America Artificial Organ Market – By Type
    • 10.1.1.Artificial Kidney
    • 10.1.2.Artificial Heart
    • 10.1.3.Cochlear Implants
    • 10.1.4.Artificial Pancreas
    • 10.1.5.Others
  • 10.2. Latin America Artificial Organ Market – By Country
    • 10.2.1.Brazil
    • 10.2.2.Mexico
    • 10.2.3.Rest of Latin America

Chapter 11. Middle East & Africa Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 11.1. Middle East & Africa Artificial Organ Market – By Type
    • 11.1.1.Artificial Kidney
    • 11.1.2.Artificial Heart
    • 11.1.3.Cochlear Implants
    • 11.1.4.Artificial Pancreas
    • 11.1.5.Others
  • 11.2. Middle East & Africa Artificial Organ Market – By Country
    • 11.2.1.UAE
    • 11.2.2.Saudi Arabia
    • 11.2.3.Turkey
    • 11.2.4.Rest of Middle East & Africa

Chapter 12. Competitive Analysis

  • 12.1.1.Competition Dashboard
  • 12.1.2.Company Profiles
    • 12.1.2.1. Edwards Lifesciences Corp.
    • 12.1.2.2. HeartWare International, Inc.
    • 12.1.2.3. Abiomed, Inc.
    • 12.1.2.4. Cochlear Limited
    • 12.1.2.5. Boston Scientific Corporation
    • 12.1.2.6. B. Braun Melsungen AG
    • 12.1.2.7. Getinge AB
    • 12.1.2.8. Baxter International Inc.
    • 12.1.2.9. Medtronic PLC
    • 12.1.2.10. Fresenius Medical Care
Report Synopsis

North America dominated the artificial organs market in 2018 and is expected to do so over the forecast period.

An artificial organ is a medical device embedded or implanted into the human body to simulate or improve the organ’s biological function. Increasing the incidence of cardiovascular diseases (CVDs) such as heart disease, strokes, chronic kidney disease, diabetes, increasing aging populations and hearing disorders are likely to boost artificial organ demand. The spike in unhealthy diets and physical inactivity, in turn, might have led to an increase in cardiovascular disorders and chronic conditions, and resulting in higher demand for devices such as total artificial hearts and pacemakers.

One of the major trends gaining popularity in the global artificial organs industry is the advent of total artificial hearts (TAH). TAH has started to emerge as a successful treatment option for end-stage biventricular heart failure patients. Its use in a heart-to-heart transplant technique has previously been approved globally. As a matter of fact, this artificial organ market analysis underlines that, over the forecast period, such factors will keep driving the global artificial organ market at a fastest CAGR of nearly 11%.

Organ necessity exceeds the supply of donated organs. Even today, there are lots of elderly patients for organ transplants, but not everybody can get it done due to the current limited supply of organ transplantation. According to the American Transplant Foundation, in the United States, around 122,000 patients are waiting for organ transplants and nearly 20 people are dying every day due to organ transplants shortages. Not only is organ shortage a problem, it is also a major issue to find a correct organ for the body. Biomedicine is a growing shift in the world of science to solve this issue. Biomedicine is a medical research division that seeks genetic and other biological-science values for the growth of artificial organs in medical practice. It is possible to deliver the right organ to the patient at the right time due to biomedicine. Biomedicine is therefore a spark of hope for those who experience organ failure.

The growing number of renal failure and dialysis due to faulty way of living, excessive number of accidents, rapid ageing population, illnesses and increased number of individuals waiting for organ transplants are the main factors that drive the market. Researchers are carrying out studies on renewable energy cells that could use human body glucose and oxygen to produce electricity. Such factors give the artificial organ industry a potential to grow further at a significant rate.

Several companies work on developing artificial organs with improved comfort for patients. Companies are also making significant R&D investments to satisfy end-user requirements, which are expected to boost demand for artificial organs further. The key global players of Artificial Organ market are Edwards Lifesciences Corp., HeartWare International, Inc., Abiomed, Inc. Cochlear Limited, Boston Scientific Corporation, B. Braun Melsungen AG, Getinge AB, Baxter International Inc., Medtronic PLC, and Fresenius Medical Care.

Report Description

Artificial organs are engineered equipment that are inserted in a human body to fill or operate a particular function of a biological organ. They are composed of the plastic seeded from the transplant recipient with stem cells, therefore the immune system of the body does not refuse to accept the unnatural organ. These machines do not have to be continually tied to a power source or any other static resource and can keep patients with severe organ failure safe and working for a long time.

The key factors driving the artificial organ market are the ageing global population and a subsequent rise in the number of people who suffer from organ failures. The demand for artificial organs has resulted due to the increasing road accidents and injuries leading to surgical procedures coupled with increasing public awareness of advances in medical technology. On the other hand, it is expected that high transplantation costs and minimal surgical expertise will limit market growth in most regions. However, when required, the absence and shortage of organ donors has encouraged the development of new technologies for artificial organs worldwide.

Artificial kidney segment is believed to have the biggest size in the market and is expected witness strong growth throughout the forecast period. The End-Stage Renal Disease (ESRD) tends to affect more than 600,000 patients per year in the United States and an approximately 1.8 million patients globally. Those living with ESRD make up only less than 1% of the Healthcare-covered population, but make up 5% to 7% of the Healthcare budget. Every year, the percentage of patients diagnosed with ESRD in the United States is growing by 4% to 5%.

Depending on the treatment with ESRD, mortality rates vary. Those on medication have a mortality rate of 25-30 percent after one year of diagnosis, with a life expectancy of 30-35 percent for five years. As survival rates increase due to medication, there is increased demand for unnatural kidneys, which drives this segment’s growth.

North America presently dominates the artificial organs market, and its stronghold is expected to continue for a few years to come. Due to excessive increased demand for artificial organs, this region is projected to increase its share of the market in the future. Each year, the U.S. spends a significant portion of its gross domestic product on medical care. According to the Organization for Economic Co-operation and Development (OECD)’s latest 2018 report, about 18% of Gross domestic product is spent on healthcare. A substantial portion of this goes into transplants in the United States. The United States thus continues to hold the largest proportion in the North American artificial organ market.

The market for artificial organs is competitive and consists of several major players. With reference to market share, the industry is currently controlled by few of the major players. Nevertheless, mid-size to smaller businesses are expanding their market presence with product innovations and technological advancements by bringing in new technologies with lower costs.

The key global players of Artificial Organ market are Edwards Lifesciences Corp., HeartWare International, Inc., Abiomed, Inc. Cochlear Limited, Boston Scientific Corporation, B. Braun Melsungen AG, Getinge AB, Baxter International Inc., Medtronic PLC, and Fresenius Medical Care.

Table of Content

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025 – Key Industry Dynamics

  • 3.1. Key Market Drivers
  • 3.2. Key Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Future Trends
  • 3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

Chapter 5. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025 – By Type

  • 5.1. Artificial Kidney
  • 5.2. Artificial Heart
  • 5.3. Cochlear Implants
  • 5.4. Artificial Pancreas
  • 5.5. Others

Chapter 6. Global Artificial Organ Market – Analysis and Revenue Forecast 2018-2025 – By Region

  • 6.1. North America
  • 6.2. Europe
  • 6.3. Asia-Pacific
  • 6.4. Latin America
  • 6.5. Middle East & Africa

Chapter 7. North America Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 7.1. North America Artificial Organ Market – By Type
    • 7.1.1.Artificial Kidney
    • 7.1.2.Artificial Heart
    • 7.1.3.Cochlear Implants
    • 7.1.4.Artificial Pancreas
    • 7.1.5.Others
  • 7.2. North America Artificial Organ Market – By Country
    • 7.2.1.U.S.
    • 7.2.2.Canada

Chapter 8. Europe Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 8.1. Europe Artificial Organ Market – By Type
    • 8.1.1.Artificial Kidney
    • 8.1.2.Artificial Heart
    • 8.1.3.Cochlear Implants
    • 8.1.4.Artificial Pancreas
    • 8.1.5.Others
  • 8.2. Europe Artificial Organ Market – By Country
    • 8.2.1.Germany
    • 8.2.2.France
    • 8.2.3.UK
    • 8.2.4.Spain
    • 8.2.5.Italy
    • 8.2.6.Rest of Europe

Chapter 9. Asia-Pacific Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 9.1. Asia Pacific Artificial Organ Market – By Type
    • 9.1.1.Artificial Kidney
    • 9.1.2.Artificial Heart
    • 9.1.3.Cochlear Implants
    • 9.1.4.Artificial Pancreas
    • 9.1.5.Others
  • 9.2. Asia-Pacific Artificial Organ Market – By Country
    • 9.2.1.China
    • 9.2.2.India
    • 9.2.3.Japan
    • 9.2.4.South Korea
    • 9.2.5.Rest of Asia-Pacific

Chapter 10. Latin America Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 10.1. Latin America Artificial Organ Market – By Type
    • 10.1.1.Artificial Kidney
    • 10.1.2.Artificial Heart
    • 10.1.3.Cochlear Implants
    • 10.1.4.Artificial Pancreas
    • 10.1.5.Others
  • 10.2. Latin America Artificial Organ Market – By Country
    • 10.2.1.Brazil
    • 10.2.2.Mexico
    • 10.2.3.Rest of Latin America

Chapter 11. Middle East & Africa Artificial Organ Market – Analysis and Revenue Forecast 2018-2025

  • 11.1. Middle East & Africa Artificial Organ Market – By Type
    • 11.1.1.Artificial Kidney
    • 11.1.2.Artificial Heart
    • 11.1.3.Cochlear Implants
    • 11.1.4.Artificial Pancreas
    • 11.1.5.Others
  • 11.2. Middle East & Africa Artificial Organ Market – By Country
    • 11.2.1.UAE
    • 11.2.2.Saudi Arabia
    • 11.2.3.Turkey
    • 11.2.4.Rest of Middle East & Africa

Chapter 12. Competitive Analysis

  • 12.1.1.Competition Dashboard
  • 12.1.2.Company Profiles
    • 12.1.2.1. Edwards Lifesciences Corp.
    • 12.1.2.2. HeartWare International, Inc.
    • 12.1.2.3. Abiomed, Inc.
    • 12.1.2.4. Cochlear Limited
    • 12.1.2.5. Boston Scientific Corporation
    • 12.1.2.6. B. Braun Melsungen AG
    • 12.1.2.7. Getinge AB
    • 12.1.2.8. Baxter International Inc.
    • 12.1.2.9. Medtronic PLC
    • 12.1.2.10. Fresenius Medical Care
Report Methodology
Report Customization
Report Sample
Consult the Analyst